Chapter 20: Non-Hodgkin Lymphomas

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Okay, let's unpack this.

A single term, lymphoma, really hides a whole spectrum of distinct diseases.

When people hear that word, they often default to the, I guess, more straightforward Hodgkin type.

But today, we're diving deep into the non -Hodgkin world.

And this is a massive, complex landscape of clonal lymphoid tumors that is just constantly evolving in how we classify and treat it.

It really is.

What's fascinating here is the sheer clinical and pathological variability.

Non -Hodgkin lymphomas, or NHL, are overwhelmingly of B cell origin.

We're talking about 85 % of cases.

The remaining 15 % or so stem from T or NK cells, natural killer cells.

So our mission today is the systematic deep dive derived directly from the essential hematology text.

We need to systematically explore this group, its classification, the underlying pathology, how it presents clinically, and of course, the modern cutting -edge strategies we use for diagnosis and treatment.

And understanding this is so crucial because the disease itself is just so common.

We're talking about a malignancy whose incidence has risen, well, pretty markedly over the past few decades.

With an approximate incidence of 17 in 100 ,000 in the UK, for instance, NHL has become the fifth most common malignancy in many developed countries.

So this isn't some niche academic topic.

It's central to daily clinical practice, and the stakes are incredibly high.

Absolutely.

One of the very first things a clinician has to establish is the fundamental distinction between the slow -moving or what we call indolent types, which are notoriously difficult to cure, and the aggressive, rapidly proliferative types, which, a bit counter -intuitively, are often curable with intensive treatment.

So it's a real paradox.

The more aggressive it is, the better the chance of a cure.

In many cases, yes.

And unlike Hodgkin lymphoma, NHL is defined by a highly irregular pattern of spread and a tendency for the disease to show up outside the lymph nodes.

We call that extranodal involvement.

The moment a diagnosis is made, the subtype classification dictates the urgency of your entire therapeutic plan.

So let's begin right there with the structure.

We've established that this is a profoundly heterogeneous group.

If we were trying to map this universe of disease for you, where do we start that initial breakdown?

We start with lineage.

As I mentioned, the dominant lineage is B cell, accounting for roughly 85 % of all NHL cases.

The other 15 % are T cell or NK cell derived.

And this initial split is functionally vital because B cell lymphomas are the target of some of our most universally effective therapies.

You're talking about the monoclonal antibodies.

Exactly.

Particularly the anti -CD20 monoclonal antibodies.

When we're dealing with the T cell lymphoma, the whole approach and the prognosis often change dramatically.

And when we look at how these are officially categorized, we're relying on the comprehensive WHO framework.

I think it's important to stress that this isn't just based on what the tissue looks like under a basic microscope.

That's right.

The World Health Organization, or WHO classification, moves far beyond simple morphology.

It's a multi -dimensional approach.

It incorporates detailed histology, of course, but also the age of the patient, the primary site of involvement.

So where is it?

Is it in the skin, the CNS, the gut?

Precisely.

And most critically, the detailed immunophenotype, what markers the cells express, and the genotype, what translocations or mutations are present.

It formally groups NHL alongside things like chronic lymphoid leukemias and myeloma, placing them under the umbrella of mature B cell and T cell neoplasms.

This holistic approach is what allows us to distinguish, say, an aggressive, diffuse large B cell lymphoma from a slower but morphologically similar lymphocytic lymphoma.

I find the cell of origin analogy to be the clearest conceptual tool here.

It helps visualize why these different lymphoma subtypes act so differently, because they're mimicking normal B cells that are sort of phrasing at different moments in their life cycle.

Exactly.

We need to journey.

It begins in the bone marrow, moves to secondary lymphoid tissues like the spleen or lymph nodes, enters what we call the germinal center or GC to refine its antibody specificity, and finally exits as a plasma cell or a memory B cell.

B cell lymphomas really represent a malignant expansion of cells that are arrested at distinct points along that pathway.

Could you walk us through a couple of those arrested stages and how they relate to a common lymphoma?

Certainly.

Think about cells that haven't yet entered the full maturation and hypermutation process, like the cell of origin for mantle cell lymphoma or a large proportion of B cell chronic lymphocytic leukemia.

When we examine their immunoglobulin genes, they often present as unmutated.

They are precursors in a way.

Now you contrast that with something like follicular lymphoma, diffuse large cell lymphoma, or even marginal zone lymphoma.

These derive from cells that have gone through or are coming out of the germinal center.

They've gone that hypermutation process and therefore their immunoglobulin genes often show mutated characteristics.

So identifying these specific phenotypic patterns, the CD markers, the cell expresses, and the mutation status of its egg genes.

That is the absolute foundation for precise classification and predicting behavior.

And that deep dive into the cell's history naturally sets up the crucial distinction between low grade and high grade disease, which as you emphasized earlier, completely dictates the management strategy.

This is the concept for NHL.

We have to divide them into two fundamental groups.

First you have the low grade or indolent lymphomas.

These are malignancies that are relatively slow moving.

They respond well to initial therapy, whether it's chemo or immunotherapy, and often confer a lengthy median survival.

We're talking 10 years or more for types like follicular lymphoma.

But, and this is the key point, the tragedy of indolent lymphomas is that they are extremely difficult, often impossible, to cure with standard therapy.

They're diseases of long -term management.

Right.

And the second group.

The second group is the high grade or aggressive lymphomas.

These are rapidly proliferative.

They multiply quickly and must be treated urgently, sometimes within hours, because if you leave them unchecked, they can be rapidly fatal.

The good news is that because they are so aggressively proliferative, they are highly sensitive to chemotherapy, and this makes them significantly more often curable.

We are truly swinging for the fences here with curative intent.

So we have two completely different therapeutic goals dictated by that single pathological assessment.

For low grade tumors, the immediate goal is control, managing symptoms, maximizing quality of life over a long period.

For high grade, it's immediate aggressive eradication.

Exactly.

You would never rush to give aggressive toxic chemotherapy to an asymptomatic patient.

Conversely, delaying treatment for an aggressive lymphoma is simply not an option.

That distinction fundamentally flips the entire therapeutic approach.

Before we move on, we need to acknowledge the confusion that exists between leukemia and lymphoma, particularly in this non -Hodgkin world.

It sounds like they aren't always neatly separated categories.

Oh, the lines are constantly blurred in hematology.

In NHL, the distinction often just comes down to the primary location of the disease burden.

The perfect example is chronic lymphocytic leukemia, CLL, and small lymphocytic lymphoma, SLL.

Biologically, morphologically, immunophyletically, they are the exact same disease.

So what's the difference then?

SLL presents primarily in the lymph nodes and solid organs, so it meets the definition of lymphoma.

CLL presents predominantly in the bone marrow and circulation, the blood meeting the definition of leukemia.

The threshold is an arbitrary cell count in the blood.

Similarly, the aggressive lymphoblastic lymphomas are virtually identical to acute lymphoblastic leukemia, A -all, and are often treated with comparable intensive regimens.

It truly is one spectrum of disease, with different names based on where the cells predominantly accumulate.

That groundwork is essential.

Now, let's pivot from what these diseases are to how they begin.

The pathogenesis.

We know the cause of most NHL is still unknown, but we can't talk about etiology without focusing on that interplay between genetics and external factors, particularly infection.

The pathogenesis picture is a fascinating blend of, well, genetic vulnerability meeting environmental triggers.

The strong link between specific infectious agents and subsequent lymphoma subtypes is one of the most powerful insights we have into how the disease gets started.

Let's detail some of those key microbial associations.

I think many people would be surprised that a common infection could actually drive cancer development.

They are powerful drivers because they often stimulate chronic immune activity, which is destabilizing to BNT cells.

Consider these relationships.

The human T -lymphotropic virus type 1, HTLV1, is definitively linked to adult T -cell leukemia lymphoma.

Epstein -Barr virus, EBV, is highly associated with Birkitt lymphoma, certain types of Hodgkin lymphoma, and extranodal NKT cell lymphoma.

Human herpesvirus 8, or HHV8, is the cause of primary fusion lymphoma and multicentric Castleman disease.

And it's not just viruses.

No, not at all.

Even common bacteria play a role.

Chronic helicobacter pylori infection in the stomach often precedes gastric multilymphoma.

Chlamydia trachomatis has been linked to ocular and nexal mumps lymphoma.

And of course, we see significantly increased incidence of aggressive lymphomas in HIV positive patients due to that chronic immune dysregulation.

So in these cases, the infectious agent or the chronic inflammation it causes provides the necessary background chaos, the environment, for the second critical step to occur, which is the actual genetic catastrophe.

Precisely.

The most frequent genetic event driving B -cell neoplasms is a cytogenetic abnormality, almost always a chromosomal translocation involving the immunoglobulin, or Ig genes.

The Ig loci are on chromosomes 2, 14, and 22.

And these areas are incredibly active and vulnerable to breakage and misrepair because B -cells intentionally manipulate and rearrange these genes to create diverse antibodies.

So if that region is already highly active and prone to breaking, what happens when an oncogene accidentally ends up right next to it?

It results in catastrophic overexpression.

The translocation essentially moves a powerful oncogene, let's use MYC -BCL2 dollars, or CCND -DGOL as examples, right next to the superactive promoter elements of the Ig locus.

This locks the oncogene into a perpetual on -state where it's constitutively and aberrantly expressed independent of normal regulatory signals.

And that leads to?

That leads the uncontrolled cellular processes that define cancer, disrupting the cell cycle, as CCND -1 does in mantle cell lymphoma, causing a failure of apoptosis, as BCL2 -2 does in folliculocular lymphoma, or driving extremely rapid proliferation, as MY -SILR does in Burkitt lymphoma.

That sounds complicated enough just listing one or two primary translocations, but the insights from next -generation sequencing have shown us the genetic landscape is far, far messier than just a single event.

Oh, it is exceptionally complex, and this explains why these diseases are so heterogeneous.

Modern sequencing reveals that a single NHL presentation can harbor upwards of 80 somatic mutations.

And these aren't just isolated random hits, they affect entire regulatory pathways.

We see mutations in genes involved in chromatin remodeling, which controls how DNA is accessed, disturbances in the NF -kappa -B B -cell activation pathway, aberrations in pre -mRNA splicing.

This layered genetic complexity contributes directly to the variable behavior and therapy resistance we see clinically.

It's not just one switch being flipped, it's the entire control panel malfunctioning.

Moving from the microscopic to the macroscopic, let's talk about the clinical side.

Given this irregular pattern of spread, how does a patient typically present with NHL?

We can categorize the clinical presentation into five main areas, and it's rare to see a patient who only fits neatly into one.

First, and most common, is superficial lymphadenopathy.

This is simply a patient noticing one or more painless, often asymmetrical, enlarged lymph nodes in peripheral areas like the neck, armpit, or groin.

Okay, that's the classic lump.

Exactly.

Second, the constitutional symptoms, the famous B symptoms, which are the red flags,

unexplained fever, drenching night sweats severe enough to soak the sheets, and significant unexplained weight loss.

These are less frequent in NHL than in Hodgkin lymphoma, but their presence immediately signals advanced, more disseminated disease.

It tells you it's systemic.

It does.

Third, a specific but notable presentation is oropharyngeal involvement.

Around five to ten percent of patients involve Waldyer's ring, which is the lymphoid tissue in the back of the throat.

This can manifest as a persistent, unusual sore throat, difficulty swallowing, or in kids with Burkitt lymphoma, rapid obstruction leading to noisy breathing.

Since NHL is a systemic disease of the blood system, it often infiltrates the bone marrow, which then leads to issues with blood cell production.

That's the fourth category, presenting symptoms related to cytopenias.

This includes anemia, which causes severe fatigue,

neutropenia, leading to recurrent or severe infections,

or thrombocytopenia, causing easy bruising or bleeding.

These cytopenias can be a primary result of diffuse infiltration of the bone marrow by lymphoma cells, or they can be secondary, resulting from an autoimmune destruction of blood cells, or simply due to sequestration in a massively enlarged spleen.

And finally, that tendency for NHL to involve sites outside the typical lymph node chain.

Yes.

The fifth category, which is critical, is abdominal and extranodal disease.

We frequently see involvement of the liver and spleen and the retroperitoneal nodes deep within the abdomen.

After the bone marrow, the single most common extranodal site is the gastrointestinal tract.

Leading to a host of acute or subacute abdominal symptoms like pain, bleeding, or obstruction.

And we can't forget involvement of other distant organs, skim, brain, testis, or thyroid, which in some cases, like mycosis fungoids, can be the primary manifestation of the disease.

Okay, so diagnosis is where we converge all these tools, the morphology, the genetics, the cell markers, to define the exact enemy we're fighting.

What is the absolute gold standard for achieving a definitive diagnosis?

The definitive investigation must be a high -quality tissue sample.

A whole lymph node excisional biopsy is ideal, or at least deep, generous core needle biopsy.

And this is a crucial point.

Fine needle aspiration, or FNA, is rarely, if ever, sufficient.

Why is that?

Lymphoma diagnosis hinges on seeing the overall architectural features of the node.

Is it diffuse?

Is it follicular?

What is the surrounding reaction?

And that architectural information is completely lost when you just suck up a few cells in an FNA.

So the pathologist isn't just looking at the cells, but at the whole tissue structure.

Can you describe those key patterns that guide them?

Pathologists look for two fundamental histological patterns.

One is the diffuse pattern, where the normal healthy structure of the lymph node is totally obliterated and replaced by a homogeneous sheet of neoplastic cells.

This is typical of diffuse large B -cell lymphoma or small lymphocytic lymphoma.

The other is the follicular or nodular pattern, which is the hallmark of follicular lymphoma.

Here, the neoplastic cells cluster into distinct nodules like tightly packed grapes.

But crucially, these abnormal nodules lack the protective mantle of small healthy lymphocytes that you'd see in a benign reactive node.

Once the morphology gives us that basic pattern, we refine the lineage using immunophenotype and clonality markers.

This involves understanding that whole alphabet soup of CD markers.

That's right.

Immunophenotypic analysis, done either through flow cytometry or immunohistochemistry, identifies the specific cluster of differentiation, or CD antigens on the tumor cell surface.

This is vital because specific disease subtypes have specific signatures.

For example, finding cells that are positive for CD20 and CD5, but negative for CD23, immediately narrows the list, strongly suggesting mantle cell lymphoma.

Clinicians use detailed tables listing these marker combinations to make a differential diagnosis.

But the real clincher for proving malignancy, especially in B -cell lymphoma, is confirming clonality.

What does that concept mean in practice?

Clonality proves that all the neoplastic cells originated from a single ancestor cell, confirming it is a cancer, not just an overactive immune response.

For B -cells, we look at the surface immunoglobulin light chains, kappa and lambda.

In a healthy reactive node, B -cells are polyclonal.

You have a mixture of different B -cell clones, so you see a balanced expression of both kappa and lambda light chains.

So it's a mix.

It's a mix.

The critical finding for a B -cell lymphoma is that the cells express only one type, either only kappa or only lambda light chains.

This monoclonal expression proves the proliferation is neoplastic.

It's a cornerstone of the diagnosis.

That is a fundamental distinction that helps separate cancer from just a chronic infection.

Moving to routine lab work, what basic blood and tissue tests provide essential staging and prognostic information?

Routine lab investigations are crucial.

First,

blood counts.

We look for anemia, neutropenia, or thrombocytopenia.

If the counts are low, it strongly suggests bone marrow involvement.

Second, the peripheral blood film.

Sometimes, even if the disease is mainly in the nodes, we find circulating malignant cells in the blood.

Third, a marrow biopsy.

A trephine biopsy is necessary for accurate staging, especially in aggressive, high -grade cases, or if PETE imaging suggests bone involvement.

Fourth, and this is key, prognostic markers.

Serum lactate dehydrogenase, or LDH, is a key one.

It's a general measure of cellular turnover, and raised levels signal rapidly proliferating cells or high tumor bulk.

We also always check for a pair of protein via immunoglobulin electrophoresis, especially in lymphoplasmicitoid lymphoma.

And we must check HIV status, as it drastically impacts prognosis and treatment choices for certain subtypes, like brachial lymphoma.

Cytogenetics then provides the final piece of the puzzle.

The specific molecular identity or signature that confirms the subtype, often more reliably than morphology alone.

They're the molecular ID card.

We look for these specific chromosomal translocations because they are diagnostic and prognostic.

For follicular lymphoma, the signature is T1418, which causes overexpression of the anti -epoptotic BCL22 gene.

For mantle cell lymphoma, it's defined by T1114, leading to overexpression of the cell cycle regulator CCND -DELO11.

Burkitt lymphoma is defined by T814 and its variants, leading to constitutive MY -CYL overexpression.

And anaplastic large cell lymphoma is associated with T25.

It goes on and on.

Okay, so once that detailed diagnosis is in hand, we stage the disease.

The Ann Arbor system is still used, but I've heard that in NHL, the histological subtype is often a more powerful predictor of outcome than the stage itself.

Is that right?

That's a very perceptive point.

While the four -stage Ann Arbor system is still used, stage I being localized, stage IV being widely disseminated in NHL, the aggressiveness of the specific subtype often overrides the stage.

A stage I Burkitt lymphoma still needs immediate intensive chemo, whereas a stage V follicular lymphoma might just be watched.

Staging itself relies heavily on modern imaging, primarily chest x -ray and whole -body PDCT scanning.

How does the PTCT dramatically enhance staging beyond a standard anatomical scan?

PTCT is invaluable because it performs a whole -body functional and anatomical assessment at the same time.

By injecting a radioactive sugar, FDG, we detect metabolic activity.

Lymphoma cells are highly metabolic and light up areas of active disease nodal or extra nodal that might be missed by size criteria on a standard CT.

It's also essential for monitoring treatment response, which we standardize using the Duville criteria.

Finally, especially for high -grade NHL like DLBCL, staging alone isn't enough to predict the chance of cure.

We need risk stratification, which brings us to the NCCNIPI.

The NCCNIPI, the National Comprehensive Cancer Network International Prognostic Index, is a critical tool for high -grade NHL.

It moves beyond simple stage to quantify risk based on five key clinical and lab factors.

These are age, LDH levels, Ann Arbor stage, specifically three or four, the number of extra nodal disease sites, and performance status, which measures the patient's functional fitness.

By adding up points across these factors, we get a predictive score that helps the clinician determine prognosis and ultimately the intensity of the treatment required.

The treatment landscape for NHL has been, well, radically transformed in the last couple of decades.

If we step back, what is the core philosophy today for actively treating B -cell NHL?

The treatment philosophy is centered on aggressive combination therapy.

For B -cell lymphomas, this involves a multi -agent combination chemotherapy regimen coupled with a monoclonal antibody targeted against the tumor cell.

The anti -CD20 agents were the initial breakthrough.

But the arsenal is expanding so rapidly beyond just rituximab.

We're seeing targeted agents that inhibit specific proteins.

Yes.

The future is increasingly individualized therapy based on molecular defects.

We have oral inhibitors, things that block crucial B -cell signaling.

We use inhibitors that target BTK, Brutin's tyrosine kinase, or PI3K delta.

We also have drugs for Bcl2 inhibition, like Venetoclax, which is highly relevant to follicular lymphoma.

And then there's CRT cell therapy.

The really cutting edge stuff.

The most complex and specialized approach.

We genetically bioengineer a patient's own T -cells to recognize a B -cell antigen, usually CD19, and then re -infuse them to hunt and destroy the cancer cells.

This is now approved and standard for relapsed or refractory patients with certain aggressive B -cell subtypes.

Let's focus on the monoclonal antibodies for a moment, specifically the anti -CD20 agents like rituximab.

Since 85 % of NHL are B -cell, this is the foundation of most regimens.

Absolutely.

Targeting the CD20 antigen on the surface of B -cells is key.

Rituximab was the first.

Now we have newer generation anti -CD20 agents like opetumumab and obenutizumab.

These newer agents have distinct mechanisms of binding, and sometimes greater efficiency in inducing cell death, which might make them more effective in specific high -risk settings.

It's not enough just to know that rituximab binds to CD20.

Let's break down how that binding actually results in cell death.

Right, so once the rituximab antibody binds to the CD20 protein on the tumor cell, it activates three primary destruction mechanisms.

First is antibody -dependent cell -mediated cytotoxicity, or ADCC.

Think of this as putting a flag on the cancer cell that immune cells like NK cells can recognize and attack.

Second is complement -mediated lysis.

The antibody binding initiates the complement cascade, which ends up punching holes in the tumor cell membrane, causing the cell to burst.

And third is direct -compoptosis.

The binding itself can transmit a signal directly into the tumor cell that forces it to undergo programmed cell death.

So we're hitting the cell with three different methods of destruction just from one drug.

That explains why the introduction of rituximab was such a game -changer.

Exactly.

The combination of rituximab plus chemotherapy, or R -chemo, drastically improves survival rates across all B -cell NHL.

And finally, for the T -cell lymphomas, or specific B -cell subtypes, we might use anti -CD30 agents.

Correct.

The choice of monoclonal antibody is purely dictated by the tumor's immunophenotype.

Rituximab vedotin, for instance, is used for anaplastic large -cell lymphoma and other CD30 -positive NHL, as well as for Hodgkin lymphoma, as it targets that specific marker.

Let's put these principles into practice by looking at specific subtypes, starting with the low -grade indolent diseases, the ones we managed for years.

We touched on small lymphocytic lymphoma, SLL, earlier.

SLL is conceptually simple.

It is the solid organ manifestation of BCLL.

They share identical morphology and immunophenotype.

The artificial distinction is the cell count.

SLL is defined by having less than 5 times 10 to the 9 per liter B -cells circulating in the blood.

When lymphadenopathy is the primary feature, it's SLL, and management follows the established guidelines for BCLL.

Next, we move to lymphoplasmicytoid lymphoma, LPL, which is almost exclusively associated with Waldenstrom macroglobulinemia, or WM.

WM is an uncommon, chronic, low -grade B -cell malignancy, typically affecting men over 50.

The defining characteristic is the presence of a monoclonal IgM -pair protein in the serum, produced by the malignant cells.

What are the key clinical features of WM?

I recall the large size of the IgM molecule is crucial here.

The size is everything.

The onset is usually vague fatigue, weight loss.

But the major clinical complication is hyperviscosity syndrome.

Because IgM is a large panameric molecule, it increases blood viscosity far more dramatically than the smaller IgG or IgA pair of proteins.

This leads to symptoms like headaches, visual upset, you can often see engorged retinal veins, and neurological deficits.

It can also cause bleeding tendencies.

The diagnosis then relies on both histology and that IgM -pair protein, plus some key molecular findings.

Precisely.

Diagnosis requires finding the monoclonal serum IgM combined with bone marrow infiltration.

In nearly all cases, over 90 % have the signature MYD -8080Y mutation.

About 30 % also have CKIC -CR -404 mutations, which are linked to more extensive disease.

How is WM managed?

Do we always rush to treat?

Not if the patient is asymptomatic.

A watch and wait strategy is common until symptoms mandate intervention.

When treatment is needed, first -line therapy is often rituximab combined with chemotherapy.

We have to be cautious with rituximab alone, though, due to the flare risk.

The initial transient rise in IgM levels can acutely worsen hyperviscosity.

And for acute hyperviscosity itself, which sounds like a medical emergency.

It is treated urgently with plasmapheresis.

Since the large IgM molecule resides predominantly in the intravascular space, removing the plasma rapidly reduces the IgM burden, offering immediate relief.

Newer oral inhibitors like Ibrutinib are also increasingly becoming first -line options.

Let's discuss marginal zone lymphomas, MZL, and that role of chronic inflammation.

MZL arises from marginal zone B cells, often initiated by chronic, local inflammation, or persistent antigen exposure, which eventually leads to secondary genetic damage.

We categorize them by site.

Splenic, nodal, or molt.

Molt mucosa -associated lymphoid tissue lymphoma is the best illustration of that infectious link.

Gastric mol lymphoma is the perfect example.

It's commonly preceded by chronic helicobacter pylori infection.

In the early stages, simply eradicating the H.

pylori using a course of antibiotics can resolve the lymphoma entirely.

It's one of the rare instances in oncology where an antibiotic can cure a cancer.

That's incredible.

And how is splenic MZL managed?

Splenic MZL presents with splenomegaly and sometimes distinctive circulating villus lymphocytes.

Localized disease can often be cured with local radiotherapy.

For symptomatic disseminated patients, management involves chemotherapy or anti -CD20 antibodies.

Finally, the most common low -grade subtype, follicular lymphoma, FL.

This is the textbook example of an indolent malignancy.

It is.

FL accounts for about 25 % of all NHL, typically presenting around age 60.

And it is defined by its molecular hallmark.

The great majority of cases have the T1418 translocation.

Can you elaborate on the functional consequence of that translocation, connecting it back to the indolent nature of the disease?

The T1418 translocation causes the constitutive overexpression of the BCL22 gene.

BCL22 is an anti -apoptotic protein.

Overexpressing it means the cells are granted increased survival.

They simply refuse to die when they should.

Because the cells live forever, even if they proliferate slowly, the disease accumulates over time.

This survival advantage, not rapid growth, is why FL is so prevalent, so persistent, and so difficult to cure.

Given that survival advantage, describe the clinical course.

It is truly indolent.

The median survival is roughly 10 years, and the disease is often widespread stage 3 or IV at presentation, but asymptomatic.

Relapse, unfortunately, is near inevitable.

Crucially, there is an annual transformation risk, about 3 % per year, where the disease suddenly transforms into a far more aggressive, high -grade diffuse tumor.

This indolent course leads to that distinctive watch and wait strategy.

Why expose a patient to toxicity if they're feeling fine?

For disseminated FL, the core strategy is often watch and wait.

Delaying active therapy does not natively impact overall survival, but avoids unnecessary toxicity.

For localized stage I disease, local radiotherapy can achieve a cure.

When treatment is required, it is rituximab -based, combined with chemotherapy like RCVP or RCHOP.

And managing that long, inevitable cycle of remission and relapse?

Maintenance therapy with rituximab is standard practice, as it significantly prolongs the time until relapse, though it doesn't improve overall survival.

Since relapse is almost guaranteed, subsequent relapses require escalated therapy.

Autologous stem cell transplant can be valuable, but if the patient wants a potential cure,

allogeneic SCT using donor cells is the only realistic prospect.

Let's move to mantle cell lymphoma, MCL.

This is a fascinating subtype that defies easy categorization.

Sometimes it acts low -grade, sometimes highly aggressive.

MCL derives from pre -germinal center cells.

There's a classical nodal type, which is typically aggressive, and a leukemic non -nodal systemic type, which can sometimes have a surprisingly indolent course.

And its specific molecular hallmark is the prerequisite for diagnosis.

It is absolutely essential.

The diagnosis at MCL rests on identifying the T11 -14 translocation.

This genetic event juxtaposes the CCND1 gene

next to the constantly active immunoglobulin heavy chain gene promoter.

The result is massive uncontrolled overexpression of CCND1, which drives the rapid inappropriate proliferation characteristic of the disease.

Given its variability, how do we assess prognosis?

We rely on the Mantle Cell International Prognostic Index, or MIPI, which scores age, performance status, LDH, and leukocyte count.

Generally, the classical nodal disease is aggressive and requires immediate intensive treatment.

We pay particular attention to patients with Tp5 -33 throughout deletions or mutations, as these predict a significantly inferior outcome.

How is the treatment strategy tailored based on fitness and age for MCL?

We use risk -adapted approaches.

For older or less fit patients, less intense chemo like RCHP or Bender or Tuximab is used.

For younger, fitter patients, we use intensive regimens, often incorporating high -dose agents like methotrexate and siterabine, sometimes followed by an autologous stem cell transplant.

And the BTK inhibitors we mentioned earlier fit prominently here.

They do.

BTK is crucial for MCL's survival.

Inhibitors like ubrutin and acalabrutin are increasingly used not only for relapse therapy, but also integrated into initial treatment regimens, offering effective, less toxic alternatives.

Now, we switch gears entirely to the high -grade, aggressive, and potentially curable lymphomas, starting with the most common and arguably most important.

Diffuse Large B -Cell Lymphoma, or DLBCL?

DLBCL is the quintessential high -grade lymphoma.

It's an umbrella term for a heterogeneous group characterized by large, rapidly dividing neoplastic cells.

It demands urgent intervention.

But the great clinical success story is that over 50 % of patients with DLBCL are cured with modern archimotherapy.

You mentioned heterogeneity.

How do we break down DLBCL to better understand prognosis?

Subtyping DLBCL is critical.

Based on gene expression and immunophenotype, we classify them into the germinal center B -cell, GCB type, and the activated B -cell, ABC type.

This distinction matters deeply.

The ABC subtype is typically associated with a significantly poorer prognosis compared to the GCB subtype.

What does the patient experience clinically, given the speed of progression?

Patients present with rapidly progressive lymphadenopathy, a lump that grows quickly.

Extranodal involvement is frequent and often the primary problem, affecting the bone marrow, GI tract, kidneys, and critically, there's a risk of central nervous system involvement.

Given the urgency, diagnosis must be swift and treatment must start immediately.

Prognosis here is tightly coupled to the International Prognostic Index, the IPI.

The IPI is central to DLBCL management.

It streamlines the NCCN IPI factors into five core elements, age over 60, high LDH, poor performance status, stage 3 disease, and the number of extranodal sites.

A high IPI score signals a high risk of relapse.

We have to address the most aggressive forms, the double -hit lymphomas.

This is a high -risk entity carved out of the DLBCL group.

The most concerning are the double -expressor or double -hit DLBCLs.

Defined by aberrant expression or genetic rearrangement of MY size plus, BCL222 and MOBROBCL222 prevents death.

Having both makes the cells hyper -aggressive.

These patients have a significantly inferior prognosis and usually require intensified chemotherapy regimens beyond standard RCHOP.

What is the undisputed foundation first -line treatment regimen for standard DLBCL?

And let's detail what RCHOP stands for.

The mainstay of treatment is RCHOP.

It's a robust combination.

R for rituximab, the anti -CD20 antibody.

C for cyclophosphamide, an alkylating agent.

H for hydroxydonaruticin or doxorubicin, an anthocyclin.

O for oncovin or vincristine, a vink alkaloid.

And P for prednisolone, a corticosteroid.

This is typically given in three -week cycles for six to eight courses.

Considering the risk of CNS relapse and aggressive disease, we have to talk about prophylaxis.

CNS prophylaxis is non -negotiable for high -risk patients.

Because systemic chemo struggles to cross the blood -brain barrier, we have to administer treatment directly.

This usually involves intratheathetical chemotherapy injected into the spinal fluid or high -dose systemic methotrexate.

If RCHOP fails or the disease relapses, what are the modern salvage options?

Relapse DLBCL is a therapeutic challenge.

It requires high -dose salvage chemotherapy regimens like RICE.

If the patient responds, we consolidate with an autologous stem cell transplant.

However, for primary refractory disease or chemoresistant disease, the newest standard of care is anti -CD19 CAR RT cell therapy.

This is the cutting edge for these patients.

We should briefly mention primary central nova system lymphoma, PCNSL, as a specific DLBCL entity.

Yes, PCNSL is a rare but highly aggressive DLBCL that arises exclusively in the brain or spinal cord.

It's more common in older or immunosuppressed patients.

Treatment is centered on high -dose methotrexate.

A major clinical debate here is the use of whole -brain radiotherapy.

It's effective but carries a high risk of long -term cognitive dysfunction.

And primary mediastinal B -cell lymphoma.

PMLBCL is rare, arising in the thymus, typically in young adults.

It can be histologically confusing because it resembles Hodgkin lymphoma.

Treatment involves intensive RCHOP -like regimens, sometimes followed by radiotherapy or an autologous transplant.

Finally, the most aggressive subtype we treat,

Burkitt lymphoma.

Burkitt lymphoma is the definition of rapid growth.

It has the highest proliferative index of any neoplasm over 95%.

The universal molecular signature is the massive overexpression of the MYSO oncogene caused by the T814 translocation, MYSO of the ultimate proliferation switch.

And clinically.

Because of that speed, it often presents in children with massive, rapidly growing tumors, frequently of the jaw or abdomen.

Prognosis is surprisingly excellent, but only if treated with immediate hyperintensive chemotherapy.

We are talking hours, not days, before initiation.

Regimens like CODOX -MIDAC are used, involving extremely high doses of methotrexate, cider bean, and cyclophosphamide, always combined with mandatory intrathecal chemotherapy.

The final segment of NHL is the T -cell and NK cell group, making up about 15 % of cases.

It sounds like they are even more heterogeneous and often tougher to treat than their B -cell counterparts.

They are exceedingly diverse, and their classification is still evolving.

They are usually of the CD4 plus phenotype, and their prognosis is often, but not always, inferior to the B -cell types.

Let's touch on a few key T -cell subtypes, starting with peripheral T -cell NHL, unspecified, or PTCL -NOS.

PTCL -NOS is essentially a diagnosis of exclusion -mature T -cell lymphomas that don't fit into a specific recognized category.

They are treated initially with CHOP.

However, the prognosis is generally poor.

If the cells express CD30, the targeted antibody brontuximab can be a useful addition.

Then we have the specialized cutaneous types, mycosis fungoids and Caesare syndrome.

Mycosis fungoids is a chronic cutaneous T -cell lymphoma presenting with severe pruritus and skin lesions patches, plaques, and eventual tumors.

A key diagnostic point is that the malignant T -cells do not circulate in the blood.

Treatment is often skin -directed, phototherapy, topical chemo, or newer agents.

And Caesare syndrome is the systemic version of that.

Yes, Caesare syndrome involves generalized skin redness, lymphadenopathy, and circulating malignant T -lymphoma cells, which have distinctive folded or cerebriform nuclei.

What about anaplastic large cell lymphoma, ALCL?

ALCL is often seen in children and young adults, is CD30 positive, and is commonly linked to the T25 RANS location, leading to ALK overexpression.

ALK negative cases have a worse prognosis.

Treatment utilizes the ALK inhibitor cristoidimib, and the anti -CD30 antibody brontuximab is highly effective.

Finally, we should briefly wrap up with Castleman disease.

Castleman disease is a rare lymphoproliferative disorder that mimics lymphoma.

It has localized forms, usually curable by surgery, and multicentric forms.

The multicentric form is highly associated with HIV and HHV8 infection.

Because it can progress to B -cell lymphoma, treatment involves managing the systemic inflammation with corticosteroids, chemo, and immunotherapy.

That has been a monumental systematic deep dive into the complex world of non -Hodgkin lymphomas.

Let's crystallize the core lessons for you.

The most critical takeaway is that NHL is defined by its profound variability.

This is why precise WHO classification integrating morphology, immunophenotype, and genetics is essential.

You cannot treat until you know exactly what you are treating.

And the second point, that fundamental management pivot.

The low -grade, high -grade dichotomy dictates everything.

Low -grade is indolent, responsive, but difficult to cure think BCL2 -2 overexpression preventing cell death.

High -grade is aggressive and urgent, but often curable think, highly proliferative, MY -CISA -driven disease.

Diagnosis relies on those three inseparable pillars.

Histology, follicular versus diffuse patterns,

immunophenotyping, specific CD markers and confirming clonality, and cytogenetics, which gives us the molecular signature, those crucial translocations like T14 -18 and T11 -14.

And finally, modern treatment have been fundamentally revolutionized.

Anti -CD20 antibodies like rituximab form the backbone of therapy for B cell types, often with RCHOP.

But the future is here now, with highly effective targeted therapies like BTK and BCL2 inhibitors, and for refractory disease, the groundbreaking use of bioengineered CAR T cells.

So what does this all mean if we connect this to the bigger picture?

Given that we see such strong associations between persistent infectious agents like EBV driving Birkitt or H.

pylori driving Maltin -specific lymphoma subtypes, what critical role might chronic, low -level inflammation or persistent antigen stimulation play in driving the initial subtle genetic damage that transforms a healthy B cell into an often incurable low -grade lymphoma?

That question of initiation versus progression is where the research is focused, seeking to intervene before the cancer even begins.

The fascinating consideration for the future of preventative hematology.

Thank you for joining us on this deep dive into non -Hodgkin lymphomas.

We hope this systematic approach to the sources helped you grasp the critical distinctions necessary for understanding this disease spectrum.

We appreciate you taking the time to explore this complex chapter with us.

Until next time from the Last Minute Lecture Team.